Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

NEJM Interview: Dr. Elliot Israel on the risks and benefits of long-acting beta agonists in the treatment of asthma and COPD.

NEJM Interview: Dr. Elliot Israel on the risks and benefits of long-acting beta agonists in the treatment of asthma and COPD.

FromNEJM Interviews


NEJM Interview: Dr. Elliot Israel on the risks and benefits of long-acting beta agonists in the treatment of asthma and COPD.

FromNEJM Interviews

ratings:
Length:
16 minutes
Released:
Dec 14, 2011
Format:
Podcast episode

Description

Dr. Elliot Israel is a Professor of Medicine at Harvard Medical School and the Director of Clinical Research in the Pulmonary and Critical Care Division at Brigham and Women's Hospital, both in Boston. Stephen Morrissey, the interviewer, is the Managing Editor of the Journal. Supplement to: Chowdhury B et al. The Risks and Benefits of Indracaterol - The FDA's Review. N Engl J Med 2011;365:2247-9.
Released:
Dec 14, 2011
Format:
Podcast episode

Titles in the series (100)

The New England Journal of Medicine (NEJM) Audio interview RSS feed. NEJM (http://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice.